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ABSTRACT
Objective: Some patients with interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis
(IPF) develop a progressive fibrosing phenotype. We investigated the diagnosis and management of
non-IPF ILDs using data from a survey of physicians and from US insurance claims.
Methods: Pulmonologists, rheumatologists and internists in France, Germany, Italy, Japan, Spain, UK
and US who had managed 10 patients with non-IPF ILDs in the past year, including those with pro-
gressive fibrosing ILDs, completed an online survey. Data on US insurance and prescription claims
were obtained from a repository that aggregates data on claims routed from providers or pharmacies
to payers.
Results: In May–June 2017, 243 pulmonologists, 203 rheumatologists and 40 internists completed an
online survey. Respondents estimated that 18–32% of patients diagnosed with non-IPF ILDs develop
progressive fibrosis and that time from symptom onset to death in these patients was 61–80months.
Drug treatment was given to 50–75% of patients with non-IPF progressive fibrosing ILDs. Reasons for
patients not being treated included that physicians considered patients to have mild or slowly pro-
gressing disease, or did not believe that available treatments are effective or well tolerated.
Corticosteroids were the preferred first-line treatment for all types of non-IPF ILD. There was consider-
able heterogeneity in preferences for second- and third-line treatments. US insurance claims data from
3823 patients indicated that, in 2016, 50–75% of patients with ILDs received drug treatment (mostly
corticosteroids) for their ILD.
Conclusions: Physicians estimate that 18–32% of patients diagnosed with non-IPF ILDs develop a pro-
gressive fibrosing phenotype and that these patients experience significant delays in the diagnosis of
ILD and the detection of progressive fibrosis. Between 25% and 50% of patients with progressive
fibrosing ILDs do not receive drug therapy. There is an unmet need for effective and well tolerated
treatments for progressive fibrosing ILDs.
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Introduction
Interstitial lung diseases (ILDs) encompass a large group of
parenchymal lung disorders, including diseases of unknown
cause, as well as those related to autoimmune diseases and
environmental exposures. Idiopathic pulmonary fibrosis (IPF)
is an ILD characterized by progressive lung fibrosis, decline
in lung function, worsening dyspnea and quality of life1, and
early mortality2. Patients with types of ILD other than IPF are
also at risk of developing a progressive fibrosing phenotype3,
including those with idiopathic non-specific interstitial
pneumonia (iNSIP)4, unclassifiable idiopathic interstitial pneu-
monias (IIPs)5, connective tissue disease-related ILDs (CTD-
ILDs) such as those related to rheumatoid arthritis (RA-ILD)6
and systemic sclerosis (SSc-ILD)7, chronic sarcoidosis8, chronic
hypersensitivity pneumonitis (HP)9 and exposure-related dis-
eases such as asbestosis and silicosis10. An ATS/ERS state-
ment published in 2013 on the classification of the IIPs
proposed a classification, monitoring and treatment strategy
based on observed disease behavior11. More recently, experts
in the field have proposed that IPF be “lumped” with other
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forms of progressive fibrosing ILD that share common patho-
logical pathways and disease behavior for the purposes of
addressing the unmet need for evidence-based treatments
for these rare diseases3.
At present, no drugs are licensed for the treatment of
ILDs other than IPF, but several clinical trials are ongoing12,13
or have recently been completed14. There are no inter-
national treatment guidelines for forms of ILD other than
IPF2,15 and SSc-ILD16,17. Treatment decisions are hampered
by a lack of high-quality evidence on the efficacy and safety
of specific therapies.
Few data are available on current practice in the diagnosis
and management of progressive fibrosing ILDs other than
IPF. Using data from an online survey of physicians and US
insurance claims, we investigated the journey that patients
with non-IPF progressive fibrosing ILDs take through diagno-
sis and management.
Methods
Pulmonologists, rheumatologists and internists in the US,
France, Germany, Italy, Spain, UK and Japan were invited via
email to complete an online survey. The physicians invited to
participate were part of an existing panel that received sur-
veys on various topics. To be eligible to participate in this
particular survey, physicians had to spend 75% of their pro-
fessional time managing patients and to have managed 10
patients with non-IPF ILDs in the past year, including those
with progressive fibrosing ILDs. Progressive fibrosing ILDs
were defined in the survey as those with fibrosis detected by
high resolution computed tomography (HRCT) (reticular
abnormality with traction bronchiectasis with or without
honeycombing) that were progressing in terms of worsening
of lung function (FVC and/or DLCO) and/or respiratory symp-
toms and/or chest images. Rheumatologists were asked to
respond to questions related to autoimmune ILDs (RA-ILD,
SSc-ILD, other CTD-ILDs) only. The survey was completed in
May–June 2017.
US insurance claims were analyzed from the Decision
Resources Group (DRG) Real World Evidence Repository,
which aggregates data from clearing houses that route
claims from providers or pharmacies to payers. This reposi-
tory includes adjudicated medical claims data from inpatient
and ambulatory settings, pharmacy claims data, electronic
health records and linkages of patients across these data
sets. It represents over two-thirds of US claims and includes
data from 98% of US health plans. Patients were categorized
as having ILD if they had 2 claims with an ILD diagnosis
and 1 visit to a pulmonologist between 2014 and 2016.
Patients were classified into ILD subtypes based on
International Statistical Classification of Diseases and Related
Health Problems (ICD) codes (see Supplementary Tables S1
and S2). The type of physician who filed the first ILD claim
was analyzed in patients who had ILD (as categorized above),
whose first ILD claim was made in 2015 or 2016, and who
had a claim for any indication 180 days prior to the first
ILD claim. The latter restriction was included to improve sta-
bility of the dataset and increase the likelihood that the
claim being analyzed was indeed the first ILD claim. To
assess the number of visits to a pulmonologist in a given
year, the number of visits in 2014 was analyzed in patients
who had ILD (as categorized above) and had 1 ILD claim in
each of 2014, 2015 and 2016. To assess the number of visits
to a rheumatologist in a given year, the number of visits in
2014 was analyzed in patients who had ILD (as categorized
above), had 1 ILD claim in each of 2014, 2015 and 2016,
and who saw a rheumatologist at least once between 2014
and 2016. To assess treatment patterns, the drugs used to
treat ILDs in 2016 were analyzed in patients who had ILD
(as categorized above), had 1 ILD insurance claim in 2016
and had 1 pharmacy claim in January–March and
October–December 2016 (to ensure they were in the data-
base consistently over the year). The drugs included in the
analysis were azathioprine, cyclophosphamide, cyclosporine,
mycophenolate mofetil, prednisolone, prednisone, rituximab
and tacrolimus. Rituximab was not included in the results as
so few patients received it (0.08%). Data are presented
descriptively.
Results
The online survey was completed by 486 physicians from the
US (n¼ 203), Japan (n¼ 80), Germany (n¼ 41), France
(n¼ 41), the UK (n¼ 41), Italy (n¼ 40) and Spain (n¼ 40), of
whom 243 were pulmonologists, 203 were rheumatologists
and 40 were internists.
Based on US claims data, a total of 113,752 patients were
categorized as having ILD. The number of visits to a pulmo-
nologist was analyzed based on claims data from 30,090
patients and the number of visits to a rheumatologist was
analyzed based on claims data from 4904 patients.
Treatment patterns were analyzed based on US prescription
claims from 3823 patients.
Diagnosis of interstitial lung disease
The online survey indicated that an ILD diagnosis is most
likely to be made by a pulmonologist, but autoimmune ILDs
are also commonly diagnosed by rheumatologists. These
findings were similar across countries (Figure 1). Overall, the
physicians surveyed estimated that non-IPF ILDs are typically
diagnosed 9–12 months after symptoms of ILD develop
(Figure 2).
US claims data showed that pulmonologists filed the first
claim for ILD in 64% of patients with iNSIP, 55% of patients
with HP and 52% of patients with sarcoidosis-related ILD
(see Supplementary Figure S1). In patients with autoimmune
ILDs, pulmonologists filed the first claim for ILD in 35–39% of
patients, radiologists in 12–15%, rheumatologists in 11–15%
and internists in 10–14% (see Supplementary Figure S1).
Monitoring and management of interstitial lung disease
Most of the physicians surveyed reported having follow-up
visits with patients with ILD every 2–3months, with some
differences observed between countries; 39% of physicians
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Figure 1. Percentage of patients with ILDs diagnosed by different clinical specialties. Data from online survey of physicians (pulmonologists, n¼ 243; rheumatolo-
gists, n¼ 203; internists, n¼ 40). Survey question: “What percentage of patients with the following types of ILDs are diagnosed by the following specialties?”
Examples of autoimmune ILDs provided to physicians participating in the survey were RA-ILD, SSc-ILD and other CTD-ILDs. Examples of non-IPF non-autoimmune
ILDs provided were iNSIP, HP and sarcoidosis-ILD. Rheumatologists were only asked this question in relation to autoimmune ILDs. Abbreviations. CTD, Connective
tissue disease; HP, Hypersensitivity pneumonitis; ILD, Interstitial lung disease; iNSIP, Idiopathic non-specific interstitial pneumonia; IPF, Idiopathic pulmonary fibrosis;
RA, Rheumatoid arthritis; SSc, Systemic sclerosis.
Figure 2. Patient journey in non-IPF progressive fibrosing ILDs. Data from online survey of physicians (pulmonologists, n¼ 243; rheumatologists, n¼ 203; intern-
ists, n¼ 40). Survey question: “Please estimate the average duration of the following for the different ILDs: time from symptom onset to diagnosis of ILD; time
from diagnosis of ILD to development of ILD that is fibrotic and progressing; time from development of ILD that is fibrotic and progressing to point where fibrotic
and progressing ILD is detected by physician; time from point where fibrotic and progressing ILD is detected by physician to patient death”. Rheumatologists were
only asked this question in relation to RA-ILD, SSc-ILD and other CTD-ILDs. Abbreviations. CTD, Connective tissue disease; HP, Hypersensitivity pneumonitis; IIP,
Idiopathic interstitial pneumonias; ILD, Interstitial lung disease; iNSIP, Idiopathic non-specific interstitial pneumonia; IPF, Idiopathic pulmonary fibrosis; RA,
Rheumatoid arthritis; SSc, Systemic sclerosis.
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in the UK reported having visits every 6months, while
51% of physicians in Japan reported having visits every
month (Supplementary Figure S2). Most of the physicians
reported performing pulmonary function tests every
3–6months, although 22% of physicians in Germany
reported that pulmonary function tests are not performed
regularly (Figure 3). Most of the physicians surveyed
reported performing HRCT scans every 6–12months
(Supplementary Figure S2).
Based on US insurance claims data from 2014, approxi-
mately 75% of patients with ILDs visited a pulmonologist
at least once (mean: 2.3 visits/year) (see Supplementary
Figure S3). Approximately 70% of patients with auto-
immune ILDs visited a rheumatologist at least once (mean:
2.3 visits/year) (see Supplementary Figure S3). Based on
the claims data, 50–75% of patients with ILDs received
drug treatment for their ILD in 2016. Most received corti-
costeroids. The next most commonly used treatment was
mycophenolate mofetil, which was given to 29% of
patients with SSc-ILD, 7% of patients with RA-ILD, 21% of
patients with other CTD-ILDs and 15% of patients with
iNSIP (Table 1).
Development of a progressive fibrosing phenotype
Physicians who participated in the online survey estimated
that 18–32% of patients diagnosed with non-IPF ILDs will
develop a progressive fibrosing phenotype, defined as evi-
dence of fibrosis (reticular abnormality with traction bronchi-
ectasis with or without honeycombing) detected by HRCT,
accompanied by worsening of lung function (FVC and/or
DLCO) and/or respiratory symptoms and/or chest images
(Figure 4). The non-IPF ILDs that physicians believed were
most likely to have a progressive fibrosing phenotype were
iNSIP, SSc-ILD, unclassifiable IIP and RA-ILD, with 32%, 31%,
29% and 26% of patients with these types of ILD,
Figure 3. Frequency of pulmonary function tests in patients with ILDs. Data from online survey of physicians (pulmonologists, n¼ 243; rheumatologists, n¼ 203;
internists, n¼ 40). Survey question: “In patients with ILD where you manage/help manage the ILD, on average how frequently do you check the status of the
patients’ ILD based on pulmonary function tests (e.g. FVC, DLCO, 6-minute walk)?” Abbreviations. DLCO, Diffusing capacity of the lungs for carbon monoxide; FVC,
Forced vital capacity; ILD, Interstitial lung disease.
Table 1. Percentage of US patients who received treatment for non-IPF ILDs in 2016.
Any treatmenta Corticosteroids Mycophenolate mofetil Azathioprine Cyclosporine Tacrolimus Cyclophosphamide
RA-ILD 72 69 7 9 5 3 0
SSc-ILD 74 59 29 15 5 4 1
Other CTD-ILDs 67 61 21 15 7 4 0
iNSIP 71 62 15 6 3 3 0
HP 75 74 6 8 2 1 0
Sarcoidosis-ILD 63 62 3 3 2 2 0
Other specified non-IPF ILDsb 50 49 3 2 2 1 0
Non-specified ILDsc 52 51 3 2 2 2 0
Data from US prescription claims from 3823 patients who had ILD (defined as 2 claims with an ILD diagnosis and 1 visit to a pulmonologist between 2014
and 2016), had 1 ILD insurance claim in 2016, and had 1 pharmacy claim in January–March and October–December 2016.
Abbreviations. CTD, Connective tissue disease; HP, Hypersensitivity pneumonitis; ILD, Interstitial lung disease; iNSIP, Idiopathic non-specific interstitial pneumonia;
IPF, Idiopathic pulmonary fibrosis; RA, Rheumatoid arthritis; SSc, Systemic sclerosis.
aCorticosteroids, mycophenolate mofetil, azathioprine, cyclosporine, tacrolimus or cyclophosphamide.
bAcute interstitial pneumonitis, adult pulmonary Langerhans cell histiocytosis, cryptogenic organizing pneumonia, desquamative interstitial pneumonia, idiopathic
interstitial pneumonia not otherwise specified, lymphangioleiomyomatosis, lymphoid interstitial pneumonia, respiratory bronchiolitis ILD.
cPatients with a generic claim for ILD from which the type of ILD could not be identified.
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respectively, estimated to develop a progressive fibrosing
phenotype (Figure 4). Physicians estimated that the time
from diagnosis of ILD to development of progressive fibros-
ing ILD is 11–15months, and that it takes 9–12months for
physicians to detect this progressive fibrosing phenotype.
Estimated time between detection of progressive fibrosis and
death was 30–45months, meaning that the estimated time
from onset of symptoms to death in patients with progres-
sive fibrosing ILDs was 61–80months (Figure 2).
The physicians surveyed believed that pulmonologists
take the lead in making treatment decisions in 70–87% of
patients with non-autoimmune progressive fibrosing ILDs
and 39–58% of patients with autoimmune progressive fibros-
ing ILDs (see Supplementary Figure S4). Of the
pulmonologists surveyed, 79–90% indicated that they would
initiate treatment for non-autoimmune progressive fibrosing
ILDs without consulting with another physician, except in
France and the UK where these proportions were 55% and
60%, respectively (see Supplementary Figure S5). For auto-
immune progressive fibrosing ILDs, 50–79% of the pulmonol-
ogists indicated that they would initiate treatment without
consulting with another physician, except in France where
the proportion was 35% (see Supplementary Figure S5).
Rheumatologists were split between those who would initi-
ate treatment without consulting with another physician and
those who would initiate treatment after consulting with the
managing pulmonologist, with some variation across coun-
tries (see Supplementary Figure S6).
Figure 4. Percentage of patients with non-IPF ILDs who develop a progressive fibrosing phenotype. Data from online survey of physicians (pulmonologists,
n¼ 243; rheumatologists, n¼ 203; internists, n¼ 40). Survey question: “For each of the ILD types listed below, among the patients you have seen in the past year,
please estimate what percentage of patients had an ILD that (1) had fibrosis detected by HRCT (i.e. reticular abnormality with traction bronchiectasis with or with-
out honeycombing) AND (2) was progressing in terms of worsening of lung function (FVC and/or DLCO) and/or respiratory symptoms and/or chest images”.
Rheumatologists were only asked this question in relation to RA-ILD, SSc-ILD and other CTD-ILDs. Abbreviations. CTD, Connective tissue disease; DLCO, Diffusing
capacity of the lungs for carbon monoxide; FVC, Forced vital capacity; HP, Hypersensitivity pneumonitis; HRCT, High-resolution computed tomography; IIP,
Idiopathic interstitial pneumonias; ILD, Interstitial lung disease; iNSIP, Idiopathic non-specific interstitial pneumonia; IPF, Idiopathic pulmonary fibrosis; RA,
Rheumatoid arthritis; SSc, Systemic sclerosis.
Figure 5. Percentage of patients who received treatment for non-IPF progressive fibrosing ILDs in the past year. Data from online survey of physicians (pulmonolo-
gists, n¼ 243; rheumatologists, n¼ 203; internists, n¼ 40). Survey question: “For all non-IPF ILD patients you manage that have fibrosis and progressive disease,
what percentage received drug treatment for their ILD in the past year? Examples of treatments include corticosteroids, azathioprine, or other immunosuppressants
aimed at treating the ILD”. Rheumatologists were only asked this question in relation to RA-ILD, SSc-ILD and other CTD-ILDs. Abbreviations. CTD, Connective tissue
disease; HP, Hypersensitivity pneumonitis; IIP, Idiopathic interstitial pneumonias; ILD, Interstitial lung disease; iNSIP, Idiopathic non-specific interstitial pneumonia;
IPF, Idiopathic pulmonary fibrosis; RA, Rheumatoid arthritis; SSc, Systemic sclerosis.
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Physicians estimated that, of the patients with non-IPF
progressive fibrosing ILDs that they have managed, 50–75%
received drug treatment in the past year; this was generally
similar across countries and types of ILD (Figure 5). The most
common reasons given by pulmonologists as to why patients
with progressive fibrosing ILDs did not receive drug therapy
were that patients had end-stage lung disease (45%) or mild
disease (34%), or that the available treatments were not well
tolerated (45%) or effective (33%) (Figure 6). The most com-
mon reasons given by rheumatologists for patients with pro-
gressive fibrosing ILDs not receiving drug therapy were that
patients had mild disease (49%), slowly progressing disease
(37%), or that the available treatments were not well toler-
ated (34%) or effective (32%) (Figure 6).
When pulmonologists were asked about the drugs they
use to treat fibrotic non-autoimmune ILDs, 63%, 71%, 76%
and 77% indicated that they used corticosteroids as first-line
therapy for unclassifiable IIP, iNSIP, HP and sarcoidosis-ILD,
respectively (Figure 7). Azathioprine was the most commonly
used second-line therapy for iNSIP, unclassifiable IIP and HP
(used by 33%, 29% and 24% of pulmonologists surveyed,
respectively), while methotrexate and azathioprine were the
preferred second-line therapies for sarcoidosis-ILD (used by
28% and 21% of pulmonologists surveyed, respectively). The
choice of third-line therapies for fibrotic non-autoimmune
ILDs was highly heterogeneous (and 19–25% of pulmonolo-
gists responded that there is no option for third-
line treatment).
When pulmonologists and rheumatologists were asked
about the drugs they use to treat fibrotic autoimmune ILDs,
51% and 45% indicated that they used corticosteroids as
first-line therapy for fibrotic RA-ILD and SSc-ILD, respectively
(Figure 7). Azathioprine, cyclophosphamide and
methotrexate were the preferred second-line treatments for
RA-ILD, each used by approximately 15% of those surveyed.
Cyclophosphamide, azathioprine, and mycophenolate mofetil
were the preferred second-line treatments for SSc-ILD, used
by 18%, 16% and 13% of physicians surveyed, respectively.
Rheumatologists in the US and Europe were more likely to
use mycophenolate mofetil as second-line treatment than
pulmonologists (see Supplementary Figure S7). Physicians in
Japan were more likely to use cyclosporine or tacrolimus and
less likely to use mycophenolate mofetil than physicians in
the US or Europe (see Supplementary Figure S7). The choice
of third-line therapy was highly heterogeneous (Figure 7).
Discussion
Despite growing clinical and research interest in progressive
fibrosing ILDs3,13,18–20, few data are available on the journey
that patients with non-IPF ILDs take through diagnosis and
management. Our data from an online survey of 486 physi-
cians who manage patients with progressive fibrosing ILDs
suggest a period of 9–12months between onset of symp-
toms and diagnosis of ILD. Similar delays to diagnosis have
been observed in patients with IPF21,22 and likely reflect the
non-specific symptoms of ILDs and the low awareness of
ILDs among primary care physicians. Interestingly, although
US claims data showed that pulmonologists were the clinical
specialty most likely to file the first claim for ILD, specialties
other than a pulmonologist or radiologist filed the first claim
for ILD in approximately a third of patients with HP or sar-
coidosis-ILD and almost a quarter of patients with iNSIP.
Further, US claims data showed that in 35–40% patients with
CTD-ILDs, the first claim for ILD was filed by a clinical spe-
cialty other than a pulmonologist, rheumatologist or
Figure 6. Reasons why patients with non-IPF progressive fibrosing ILDs did not receive treatment. Data from online survey of physicians (pulmonologists, n¼ 243;
rheumatologists, n¼ 203). Survey question: “In the previous question, you indicated that some ILD patients that have fibrosis and progressive disease did not
receive drug treatment for their ILD in the past year. What are the primary reasons why these patients did not take a therapy?” Abbreviations. ILD, Interstitial lung
disease; IPF, Idiopathic pulmonary fibrosis.
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radiologist. The results of the online survey suggested that a
higher proportion of cases of ILD were diagnosed by pulmo-
nologists or rheumatologists, possibly because most of the
respondents came from one of these specialties, but still that
20–30% of patients of patients with ILDs were diagnosed by
another clinical specialty. These findings suggest that there is
no established pathway for the referral and diagnosis of
patients with suspected ILDs, leading to delays in the diag-
nosis, follow-up and management of progressive fibros-
ing ILDs.
Our data suggest that patients with non-autoimmune
ILDs are managed mainly by pulmonologists, while patients
with autoimmune ILDs tend to be co-managed by pulmonol-
ogists and rheumatologists. Such a cross-disciplinary
approach is believed to be important to optimize the man-
agement of autoimmune ILDs23. Most of the physicians sur-
veyed performed pulmonary function tests every
3–6months, and HRCT scans every 6–12months, in their
patients with ILDs. A decline in FVC or an increase in fibrotic
changes on HRCT in patients with ILDs reflects disease pro-
gression and is predictive of mortality24–29. Thus regular
monitoring is important for the early detection of patients
with a progressive phenotype and could inform manage-
ment decisions and patient counseling. While no guidance
on the appropriate frequency of follow-up in patients with
non-IPF ILDs has been issued by professional associations,
the frequency of pulmonary function tests reported by physi-
cians in our survey appears to be in line with expert opinion
on best practice in the management of CTD-ILDs30,31.
Physicians who participated in the online survey esti-
mated that 18–32% of patients diagnosed with non-IPF ILDs
will develop a progressive fibrosing phenotype. Previous
studies have reported a wide range of figures for the
prevalence of progressive disease in patients with ILDs,
reflecting the different cohorts studied and the variety of cri-
teria used to define progression. However, it is clear that a
sizeable minority of patients with CTD-ILDs, chronic HP,
iNSIP, sarcoidosis-ILD and unclassifiable IIP develop a pro-
gressive fibrosing phenotype characterized by decline in
lung function, worsening symptoms and premature
death4,5,7,25,27,28,32–35. The physicians who participated in this
survey estimated that patients with non-IPF progressive
fibrosing ILDs die approximately 4–5 years after initial diag-
nosis of ILD. This is similar to the mortality of patients with
IPF prior to the availability of therapies that slow disease
progression36,37.
Data from our physician survey suggested that 25–50% of
patients with progressive fibrosing ILDs did not receive any
drug therapy in the past year. These findings are in line with
data from an online survey of 290 European physicians man-
aging patients with IPF conducted in February–March 2016
that indicated that 54% of patients with IPF, and 71% of
those with IPF considered to be mild, were not treated with
an approved antifibrotic agent38. Approximately a third of
the pulmonologists and nearly half of the rheumatologists
included in our online survey indicated that a primary reason
for not initiating therapy in patients with progressive fibros-
ing ILDs was that patients were considered to have a “mild”
level of disease. That rheumatologists were more likely than
pulmonologists not to initiate treatment for this reason may
reflect pulmonologists having a better understanding of the
unpredictable course of ILDs and the poor prognosis associ-
ated with disease progression. Approximately a third of pul-
monologists and rheumatologists indicated that the reason
for not initiating therapy was a lack of effective therapies,
while similar numbers indicated that the reason was that
Figure 7. Agents used as first-, second- and third-line treatments for fibrotic ILDs. Data from online survey of physicians (non-autoimmune ILDs: 243 pulmonolo-
gists; autoimmune ILDs: 243 pulmonologists and 203 rheumatologists). Survey question: “For the following types of ILDs where patients also have lung fibrosis,
please indicate your preferred first, second, and third line treatments for the respective ILD”. Rheumatologists were only asked this question in relation to RA-ILD
and SSc-ILD. Abbreviations. HP, Hypersensitivity pneumonitis; IIP, Idiopathic interstitial pneumonias; ILD, Interstitial lung disease; iNSIP, Idiopathic non-specific inter-
stitial pneumonia; RA, Rheumatoid arthritis; SSc, Systemic sclerosis.
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patients were unable to tolerate therapy, presumably refer-
ring to the side-effects of immunosuppressants.
By far the most commonly used first-line therapy for all
the non-IPF fibrosing ILDs we studied was corticosteroids.
This is consistent with recent data from the EXCITING-ILD
registry in Germany, which showed that prednisone was
used by two-thirds of patients with ILD19. Corticosteroids are
commonly used treatments for several types of ILD and may
lead to short-term improvements in lung function, but no
randomized clinical trials have evaluated their efficacy in
patients with progressive fibrosing lung disease.
Corticosteroids are commonly used in the treatment of SSc-
ILD39 but there is very little evidence to support their use in
these patients and they are not recommended in inter-
national treatment guidelines17 or in a treatment algorithm
recently issued by an expert consensus group40.
Cyclophosphamide and mycophenolate mofetil, which have
shown efficacy in clinical trials in SSc-ILD41,42, were named as
preferred first-line treatments for fibrosing SSc-ILD by only
12% and 11%, respectively, of the physicians who completed
the online survey. This is lower than suggested by other
studies40,43 and the reasons for this are unclear. The online
survey revealed great heterogeneity in the drugs used as
second- and third-line therapies for all the ILDs studied,
reflecting the lack of evidence available to guide therapeutic
decision-making.
To our knowledge, this is the first large survey of physi-
cians and the first study of US insurance claims to investigate
current practice in the diagnosis and management of patients
with non-IPF progressive fibrosing ILDs. Strengths of our anal-
yses include the recruitment of physicians with experience in
managing patients with ILDs to participate in the online sur-
vey, the large sample size, and the systematic collection of
data based on US insurance claims. Limitations include the
inherent biases in individuals who choose to respond to
online surveys and possible differences in the way that
respondents interpreted concepts such as worsening of lung
function and “progressive” ILD in their answers. We do not
know if physicians interpreted ILD to be progressive only if
patients did not respond to immunosuppressive treatment.
The survey required physicians to distinguish between the
time at which fibrotic and progressing ILD developed and the
time at which fibrotic and progressing ILD was detected by a
physician. It is not known how physicians estimated the first
of these time points but it may have been the last time-point
before disease progression was observed. The survey question
related to estimated survival in patients with progressive
fibrosing ILDs did not account for the presence of comorbid-
ities, such as pulmonary hypertension, which are common in
patients with ILDs and can significantly affect survival44.
Patients with autoimmune-disease-related ILDs managed
solely by a rheumatologist were not covered in the analysis of
US insurance claims data. We did not investigate the reasons
for physicians using (or not using) particular treatments for
ILDs. Physicians’ preferred treatments for ILDs are influenced
by the availability and insurance coverage of drugs in their
country or region, so data collected in specific countries may
not apply to other countries.
Conclusions
Physicians who treat patients with ILDs estimate that
18–32% of patients diagnosed with non-IPF ILDs develop a
progressive fibrosing phenotype. The journey for these
patients includes delays in the initial diagnosis of ILD and in
the detection of progressive fibrosis. Physicians estimate that
post-diagnosis survival time in patients who develop other
progressive fibrosing ILDs is similar to that of patients with
IPF prior to the availability of antifibrotic therapies. Over a
quarter of patients with non-IPF progressive fibrosing ILDs
do not receive any drug treatment. There is a high unmet
need for effective and well tolerated treatments for progres-
sive fibrosing ILDs.
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